US FDA approves 1st new Alzheimer’s drug in nearly 20 years

Global News published this video item, entitled “US FDA approves 1st new Alzheimer’s drug in nearly 20 years” – below is their description.

American government health officials have approved the first new drug for Alzheimer’s disease in nearly 20 years, disregarding warnings from independent advisers that the much-debated treatment hasn’t been shown to help slow the brain-destroying disease.

The U.S. Food and Drug Administration (FDA) said it granted approval to the drug from Biogen based on results that seemed “reasonably likely” to benefit Alzheimer’s patients.

The new drug, which Biogen developed with Japan’s Eisai Co., did not reverse mental decline, only slowing it in one study. The medication, aducanumab, will be marketed as Aduhelm and is to be given as an infusion every four weeks.

For more info, please go to https://globalnews.ca/news/7927920/biogen-alzheimers-disease-fda-approval/

Subscribe to Global News Channel HERE: http://bit.ly/20fcXDc

Like Global News on Facebook HERE: http://bit.ly/255GMJQ

Follow Global News on Twitter HERE: http://bit.ly/1Toz8mt

Follow Global News on Instagram HERE: https://bit.ly/2QZaZIB

#Alzheimers #Health #GlobalNews

Global News YouTube Channel

Got a comment? Leave your thoughts in the comments section, below. Please note comments are moderated before publication.

About This Source - Global News

Global News is the news and current affairs division of the Canadian Global Television Network, based in Vancouver, Canada.

Recent from Global News:

  • Canada’s inflation rate reaches 4.1% in August, highest since 2003
  • Shoal Lake First Nation to lift boil water advisory after 24 years
  • Gen. Jonathan Vance won’t face further charges because of high military rank
  • Leave a Comment

    We don't require your email address now, just your name. BUT, if you do add it, you may be notified if there are replies to your comment. Please make respectful comments, which add value, and avoid personal attacks on others. Comments failing to adhere to these guidelines will not be published.